Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF— alpha inhibitors
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Xeljanz
|
| Active substance |
tofacitinib citrate
|
| Therapeutic area (MeSH) |
Arthritis, Rheumatoid
|
| DHPC type |
Safety signal
|
| Human ATC code |
L04AA29
|
| Dissemination date |
24/03/2021
|